methylprednisolone has been researched along with Acute Relapsing Multiple Sclerosis in 143 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (1.40) | 18.2507 |
| 2000's | 62 (43.36) | 29.6817 |
| 2010's | 72 (50.35) | 24.3611 |
| 2020's | 7 (4.90) | 2.80 |
| Authors | Studies |
|---|---|
| Evangelopoulos, DS; Evangelopoulos, ME; Kassi, E; Moutsatsou, P; Nasiri-Ansari, N; Papadopoulou, A | 1 |
| Ashkenas, J; Borsellino, L; Leckey, R; Rawlings, AM; Suri, A | 1 |
| Bachmann, M; Bonda, V; Möhn, N; Respondek, G; Saker, F; Skripuletz, T; Stangel, M; Stoll, M; Wattjes, MP | 1 |
| Cabrera-Maqueda, JM; Carreón-Guarnizo, E; Fuentes-Rumí, L; Hernández-Clares, R; Iniesta-Martinez, F; León-Hernández, A; Meca-Lallana, JE; Morales-Ortiz, A; Valero-López, G; Zamarro-Parra, J | 1 |
| Bozzetti, S; Candelaresi, P; Capra, R; Ferrari, S; Florio, C; Gerevini, S; Höftberger, R; Maniscalco, GT; Manzo, V; Mariotto, S; Napolitano, M; Servillo, G; Spatola, M | 1 |
| Mukharesh, L; Rothstein, TL | 1 |
| Fu, X; Huang, Y; Wang, Q; Xu, Q; Zeng, S; Zhang, Y; Zou, L | 1 |
| Cinar, BP; Kahraman, T; Kosehasanoğullari, G; Kursun, BB; Oz, D; Ozakbas, S | 1 |
| Bittner, S; Groppa, S; Oberwittler, C; Uphaus, T; Zipp, F | 1 |
| Barun, B; Fabekovac, V; Habek, M; Horvat Ledinek, A; Krbot Skorić, M; Šega-Jazbec, S | 1 |
| Baschieri, F; Calabresi, P; Di Filippo, M; Di Gregorio, M; Eusebi, P; Floridi, C; Floridi, P; Gaetani, L; Gentili, L; Mancini, A; Picchioni, A; Rosi, G; Sarchielli, P | 1 |
| Bresteau, C; Perlemuter, G; Prevot, S; Voican, C | 1 |
| Rizvi, A; Shaan, F; Sharma, G | 1 |
| Gualandi, F; Lapucci, C; Laroni, A; Mancardi, G; Mikulska, M; Palmeri, S; Uccelli, A | 1 |
| Batllé-Nadal, J; Blanco, Y; Brieva-Ruiz, L; Cano-Orgaz, A; Capellades, J; Hervás-García, JV; Moral, E; Presas-Rodríguez, S; Ramió-Torrentà, L; Ramo-Tello, C; Torres, F | 1 |
| Adamec, I; Habek, M; Pavičić, T; Ruška, B | 1 |
| Finck, TLK; Fischer, HJ; Lühder, F; Pellkofer, HL; Reichardt, HM | 1 |
| Altıntaş, A; Aslan, M; Incir, S; Seven, A | 1 |
| Barkhof, F; Killestein, J; van Eijk, JJ; van Munster, ET; Verhoeff, L; Wattjes, MP; Zentjens, W | 1 |
| Zahednasab, H | 1 |
| Berenguer-Ruiz, L; Feliu-Rey, E; Sempere, AP | 1 |
| Brown, JW; Coles, AJ; Jones, JL | 1 |
| Canales, M; Du Pasquier, RA; Schluep, M | 1 |
| Bagnato, F; Bies, RR; Goñi, J; Hutmacher, MM; Troconiz, IF; Velez de Mendizabal, N; Villoslada, P | 1 |
| Abdellaoui, M; Ahdab, R; Ayache, SS; Créange, A; Farhat, WH; Lefaucheur, JP; Mylius, V; Zouari, HG | 1 |
| Azimi, AR; Najmi Varzaneh, F; Rezaei, N; Sahraian, MA | 1 |
| Alonso, B; de Andrés, C; Faure, F; Mateos, D; Ramos-Medina, R; Sánchez-Ramón, S; Teijeiro, R; Tejera-Alhambra, M; Valor, L | 1 |
| Berriosmorales, I; Cachia, D; Ionete, C; Izzy, S | 1 |
| Baiocchini, A; Del Nonno, F; Galati, V; Grilli, E; Petrosillo, N | 1 |
| Appeldoorn, CC; Gaillard, PJ; Gladdines, W; Lee, DH; Linker, RA; Reijerkerk, A; Rötger, C | 1 |
| Jiang, H; Li, XL; Wang, MX; Yan, X; Yu, CM; Zhang, B; Zhang, WJ; Zhang, ZC | 1 |
| Dang, HA; Muls, NG; Sindic, CJ; van Pesch, V | 1 |
| Federzoni, L; Ferraro, D; Losi, L; Mirante, VG; Nichelli, PF; Simone, AM; Sola, P; Villa, E; Vitetta, F | 1 |
| Coustans, M; Deburghgraeve, V; Edan, G; Hamonic, S; Laplaud, DA; Le Page, E; Lebrun, C; Veillard, D; Wardi, R; Wiertlewski, S; Zagnoli, F | 1 |
| Akpınar, Z; Anlıaçık, S; Kozak, HH; Uca, AU | 1 |
| Girgis, R; McVeigh, K; Vakros, G | 1 |
| Comi, G; Radaelli, M | 1 |
| Caster, O; Edwards, IR | 1 |
| Fox, RJ; Giovannoni, G; Gold, R; Havrdova, E; Kappos, L; Kita, M; Sarda, SP; Viglietta, V; Yang, M; Zhang, R | 1 |
| Alnek, K; Gross-Paju, K; Kannel, K; Kisand, KV; Uibo, R; Vahter, L | 1 |
| Blinkenberg, M; Dogonowski, AM; Madsen, KH; Paulson, OB; Sellebjerg, F; Siebner, HR; Sørensen, PS | 1 |
| Achiron, A; Ben-Ari, Z; Davidov, Y; Dolev, M; Har-Noy, O; Pappo, O | 1 |
| Abgrall-Barbry, G; Carle, G | 1 |
| Głąbiński, A; Jastrzębski, K; Jatczak-Pawlik, I; Jóźwiak, K; Książek-Winiarek, D; Pietruczuk, M; Wojkowska, D | 1 |
| Berkovich, RR | 1 |
| Boringa, J; Gaillard, P; Gladdines, W; Heerings, M; Hoogervorst, E; Jongen, PJ; Linssen, WH; Lönnqvist, F; Sinnige, LG; Stavrakaki, I; van der Kruijk, R; van Munster, E; Verhagen, WI; Verheul, F; Visser, LH; Voet, B | 1 |
| Balkuv, E; Basaran, R; Duruyen, S; Isbilen, B; Isik, N; Kocer, A; Varoglu, AO | 1 |
| Jahnke, B; Osuagwu, F | 1 |
| de Lastic, AL; Deraos, G; Dimisianos, N; Matsoukas, J; Mouzaki, A; Papathanasopoulos, P; Rodi, M; Sakellaraki, P | 1 |
| Markovic-Plese, S; Tao, Y; Zhang, X | 1 |
| El Nahrery, E; Gad, AH; Ghaffar, NFA; Hashem, H; Mehaney, DA; Shalaby, N; Shehata, HS; Tawfik, TZ | 1 |
| Benguría, A; De Andres, C; García, MI; García-Domínguez, JM; Goicoechea, H; López-Fernández, LA; Martín, ML; Martínez-Ginés, ML; Romero-Delgado, F; Sanjurjo, M | 1 |
| Michałowska-Wender, G; Wender, M | 1 |
| Annunziata, P; Bellini, M; De Santi, L; Menci, E; Monti, L | 1 |
| Dimitrakopoulos, A; Evangelopoulos, ME; Kararizou, E; Koutsis, G; Nikolaou, C; Rentzos, M; Rombos, A; Sfangos, C; Tsoutsou, A; Zoga, M | 1 |
| Arranz, G; López San Román, A; Moreira, VF; Moreno, A; Riesco, JM; Rivero Fernández, M; Ruiz Del Arbol, L | 1 |
| Ewa, B; Halina, BP; Jacek, R; Jacek, T; Krystyna, MS; Sebastian, R; Zbigniew, S | 1 |
| Apperson-Hansen, C; Beck, GJ; Calabresi, PA; Cohen, JA; Edwards, KR; Eickenhorst, T; Felton, WL; Fisher, E; Fox, RJ; Goodman, AD; Hara-Cleaver, C; Houghtaling, PL; Hutton, GJ; Imrey, PB; Karafa, MT; Mandell, BF; Scott, TF; Stadtler, M; Zhang, H | 1 |
| Beiske, AG; Elovaara, I; Frederiksen, JL; Mellgren, SI; Myhr, KM; Olsen, IC; Sandberg-Wollheim, M; Sorensen, PS; Svenningsson, A; Søgaard, LV | 1 |
| Clavelou, P; Créange, A; Debouverie, M; Defer, G; Jaillon-Rivière, V; Liban, D; Moutereau, A; Taithe, F | 1 |
| Beyene, J; Burton, JM; Hohol, M; O'Connor, PW | 2 |
| Xu, L; Xu, M; Xu, Z | 1 |
| Chen, X; Hu, X; Liu, M; Lu, Z; Peng, F; Wang, Y; Yang, Y; Zheng, X | 1 |
| Abellán, I; Belenguer, A; Boscá, I; Casanova, B; Coret, F; Fernández, P; Magraner, MJ; Mallada, J; Montalbán, X; Pascual, AM; Sanz, MA; Sempere, AP; Téllez, N | 1 |
| Aichner, F; Aspeck, E; Berger, T; Deisenhammer, F; Eggers, C; Ehling, R; Fazekas, F; Gneiss, C; Gotwald, T; Koudouovoh-Tripp, PM; Künz, B; Ladurner, G; Lutterotti, A; Millonig, A; Reindl, M; Ropele, S; Schautzer, F | 1 |
| Dijkstra, CD; Polman, CH; Tilders, FJ; Uitdehaag, BM; van Winsen, LM | 1 |
| Shepard, G; Sinclair, V | 1 |
| Czlonkowska, A; Czlonkowski, A; Gromadzka, G; Kurowska, K; Mirowska-Guzel, D | 1 |
| Dubois, B | 1 |
| Andersson, M; Bartholomé, E; Beer, K; Celius, EG; Constantinescu, CS; Elovaara, I; Garde, E; Jongen, PJ; Ravnborg, M; Sperling, B; Sørensen, PS | 1 |
| Barun, B; Brinar, VV; Habek, M; Puretić, Z | 1 |
| Losy, J; Szczuciński, A | 1 |
| Bojar, M; Houžvičková, E; Libertinová, J; Lišková, P; Mat'oška, V; Meluzínová, E; Mináriková, M; Nyč, O; Zajac, M | 1 |
| Börnsen, L; Khademi, M; Olsson, T; Sellebjerg, F; Sørensen, PS | 1 |
| Kalinowska-Łyszczarz, A; Losy, J; Pawlak, MA; Szczuciński, A | 1 |
| Bisaga, GN; Boĭko, AN; Mel'nik, IuB; Odinak, MM; Popova, NF | 1 |
| Comi, G; Edan, G; Filippi, M; Le Page, E; Leray, E; Rocca, MA | 1 |
| Hassinger, S; Lindquist, JA; Lindquist, S; Sailer, M | 1 |
| Bernad, A; Boscá, I; Casanova, B; Coret, F; Escutia, M; Magraner, MJ; Navarré, A; Navarro, L; Simó, M | 1 |
| Depaz, R; Lubetzki, C; Papeix, C; Stankoff, B; Tourbah, A | 1 |
| Adamec, I; Brinar, VV; Gabelić, T; Habek, M; Mrđen, A; Radoš, M | 1 |
| Fox, EJ; Gazda, SK; Lake, SL; Mayer, L; Melia, K; O'Donnell, L; Sullivan, HC | 1 |
| Andrews, M; Bergsland, N; Carl, E; Cherneva, M; Dwyer, MG; Heininen-Brown, M; Hojnacki, D; Hussein, S; Kennedy, C; Weinstock-Guttman, B; Willis, L; Zivadinov, R | 1 |
| Blair, NF; Brew, BJ; Halpern, JP | 1 |
| Byrne, S; Mason, D | 1 |
| Havla, J; Hohlfeld, R; Kümpfel, T | 1 |
| Chataway, J; McNicholas, N; Patel, A | 1 |
| Acar, M; Gedizlioglu, M; Kilinc, S; Koskderelioglu, A; Ozturk, F; Talay, N | 1 |
| Amin, OS; Shwani, SS | 1 |
| Birch, B; Boucher, O; Lyons, M; Patel, N | 1 |
| Antoniol, C; Campiche, C; Canales, M; Du Pasquier, RA; Jilek, S; Le Goff, G; Mercier, N; Pantaleo, G; Schluep, M | 1 |
| Clifford, DB; Koralnik, IJ | 1 |
| Bash, CN; Frank, JA; Howard, T; Lewis, BK; McFarland, HF; Rao, AB; Richert, N | 1 |
| Boggild, M; Ford, H | 1 |
| Barkhof, F; Hoogervorst, EL; Polman, CH | 1 |
| Braszko, JJ; Drozdowski, W; Halicka, D; Kochanowicz, J; Kułakowska, A | 1 |
| Andreoni, L; Bergamaschi, R; Cosi, V; Franciotta, D; Zardini, E | 1 |
| Folgar, S; Gatto, EM; Micheli, F; Raina, G | 1 |
| Castellà, MD; Montalban, X; Pericot, I; Río, J; Rovira, A; Tintoré, M | 1 |
| Howell, SJ; Lawry, J; Mahad, DJ; Woodroofe, MN | 1 |
| Antonijevic, IA; Steiger, A | 1 |
| Altmann, DR; Hickman, SJ; Jones, SJ; Kapoor, R; Miller, DH; Plant, GT | 1 |
| Caro, J; O'Brien, JA; Patrick, AR; Ward, AJ | 1 |
| Aichner, FT; Berger, T; Deisenhammer, F; Felber, SR; Kremser, C; Schocke, MF; Seppi, K; Wolf, C | 1 |
| Beekman, R; Lee, ML; Lenderink, AW; Movig, KL; Tijssen, CC; Uitdehaag, BM; Visser, LH | 1 |
| Bowen, JD; Severson, B; Yang, CC | 1 |
| Edan, G | 1 |
| Chatel, M; De Seze, J; Lacour, A; Lebrun, C; Masmoudi, K; Revenco, E; Rumbach, L; Verier, A; Vermersch, P; Vidry, E | 1 |
| Borràs, C; Montalban, X; Nos, C; Río, J; Sastre-Garriga, J; Tintoré, M | 1 |
| Chan, SC; Dmitrovic, J; Metz, LM; Morrow, SA; Stoian, CA | 1 |
| Haas, J; Olsson, T; Ravnborg, M; Sellebjerg, F; Sorensen, PS | 1 |
| Bourg, V; Chanalet, S; Chatel, M; Ghetau, G; Lebrun, C | 1 |
| Caputo, D; Cavarretta, R; Comi, G; Ferrante, P; Filippi, M; Iannucci, G; Oreja-Guevara, C; Rovaris, M; Sormani, MP; Valsasina, P | 1 |
| de Seze, J; Defoort-Dhellemmes, S; Marcel-Viallet, M; Vermersch, P; Wyremblewski, P | 1 |
| Bühler, R; Humm, AM; Magistris, MR; Rösler, KM; Z'Graggen, WJ | 1 |
| Andersson, BA; Haghighi, S; Lycke, J; Malmeström, C | 1 |
| Auer, DP; Blazevic, M; Daumer, M; Held, U; Holsboer, F; Kümpfel, T; Schumann, E; Schwan, M; Then Bergh, F; Trenkwalder, C; Uhr, M; Weber, F; Wismüller, A; Yassouridis, A | 1 |
| Fox, EJ | 1 |
| Butzkueven, H; Chapman, C; Cook, MJ; Kilpatrick, TJ; Litewka, L; Lovelock, C; MacGregor, LR; Mitchell, PJ; Sedal, L; Tubridy, N | 1 |
| Monteiro, LP; Moreira, MA; Teixeira, AL; Teixeira, MM; Tilbery, CP | 1 |
| Kontoangelos, KA; Kosma, KK; Papageorgiou, CC; Rabavilas, AD; Sfagos, C; Soldatos, CR; Triantafyllou, N; Vassilopoulos, D | 1 |
| Darras, BT; Eksioglu, YZ; Garbern, JY; Golomb, MR; Gorman, MP; Hobson, GM; Kinkel, RP; Urion, DK; Walsh, LE | 1 |
| Batocchi, AP; Bianco, A; Caggiula, M; Frisullo, G; Iorio, R; Katia Patanella, A; Mirabella, M; Nociti, V; Sancricca, C; Tonali, PA | 1 |
| Kalinowska, A; Losy, J; Szczuciński, A | 1 |
| Chaperon, J; Coustans, M; Edan, G; Le Page, E; Leray, E; Morrissey, SP; Taurin, G | 1 |
| De Stefano, N; Filippi, M; Hawkins, C | 1 |
| Cazzato, G; De Masi, R; Nasuelli, D; Zivadinov, R; Zorzon, M | 1 |
| Calabresi, PA; Chakraborty, S; Cohen, JA; Edwards, KR; Eickenhorst, T; Felton, WL; Fisher, E; Fox, RJ; Goodman, AD; Hara-Cleaver, C; Hutton, GJ; Imrey, PB; Ivancic, DM; Mandell, BF; Perryman, JE; Scott, TF; Skaramagas, TT; Zhang, H | 1 |
| Bernat, A; Boscá, I; Casanova, B; Coret, F; Escutia, M; Pascual, AM | 1 |
| Caon, C; Hreha, S; Khan, O; Lisak, R; Perumal, JS; Tselis, A; Zabad, R | 1 |
| Armstrong, MA; Boylan, MT; Crockard, AD; Hawkins, SA; McDonnell, GV | 1 |
| Barnes, D; Britton, T; Brown, P; Farmer, S; Francis, DA; Frankel, JP; Hughes, RA; Katifi, HA; Morris, RW; Perkin, GD; Rudge, P; Sharrack, B; Soudain, S; Swash, M; Wade-Jones, O | 1 |
| Bauer, R; Dorndorf, W; Engelhardt, B; Kern, A; Kraus, J; Oschmann, P; Schiel, C; Stolz, E; Traupe, A | 1 |
| Brusa, A; Jones, SJ | 1 |
| Khan, OA; Rothman, MI | 1 |
| Bethoux, F; Kinkel, RP; Miller, DM | 1 |
| Gold, R; Schmidt, J; Stürzebecher, S; Toyka, KV | 1 |
| Cazzato, G; De Masi, R; Grop, A; Nasuelli, D; Pozzi-Mucelli, RS; Rudick, RA; Ukmar, M; Zivadinov, R; Zorzon, M | 1 |
| Hoogervorst, EL; Kalkers, NF; Polman, CH; Uitdehaag, BM | 1 |
| Pittock, SJ; Rodriguez, M; Wijdicks, EF | 1 |
| Afsar, N; Aktan, S; Gunal, DI; Tuncer, N | 1 |
| Chalakova-Atanasova, NT; Kostadinova, II; Manova, MG; Petrova, NS; Temenlieva, VK | 1 |
12 review(s) available for methylprednisolone and Acute Relapsing Multiple Sclerosis
| Article | Year |
|---|---|
Case Report: Overlapping Multiple Sclerosis With Anti-N-Methyl-D-Aspartate Receptor Encephalitis: A Case Report and Review of Literature.
Topics: Adult; Anti-Inflammatory Agents; Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Anticonvulsants; Antipsychotic Agents; Female; Humans; Immunoglobulins, Intravenous; Immunologic Factors; Levetiracetam; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; Olanzapine; Prednisolone | 2020 |
Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies.
Topics: Adult; Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Dimethyl Fumarate; Female; Glatiramer Acetate; Hospitalization; Humans; Immunosuppressive Agents; Injections, Intravenous; Magnetic Resonance Imaging; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Randomized Controlled Trials as Topic | 2015 |
Methylprednisolone-induced liver injury: Case report and literature review.
Topics: Biopsy; Chemical and Drug Induced Liver Injury; Female; Glucocorticoids; Humans; Liver; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; Young Adult | 2016 |
Acute Multiple Sclerosis Relapse.
Topics: Acute Disease; Adrenocorticotropic Hormone; Clinical Trials as Topic; Humans; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; Plasma Exchange; Recurrence; Risk Factors | 2016 |
[Recurrent acute liver toxicity from intravenous methylprednisolone].
Topics: Acute Disease; Biopsy; Chemical and Drug Induced Liver Injury; Female; Humans; Injections, Intravenous; Liver; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Necrosis; Recurrence | 2008 |
Oral versus intravenous steroids for treatment of relapses in multiple sclerosis.
Topics: Administration, Oral; Anti-Inflammatory Agents; Glucocorticoids; Humans; Injections, Intravenous; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; Prednisone; Recurrence | 2009 |
Multiple sclerosis: from cure to care.
Topics: Environment; Genetic Predisposition to Disease; Humans; Methylprednisolone; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neuroprotective Agents; Quality of Life; Severity of Illness Index | 2009 |
[2012: Update on diagnosis and treatment of multiple sclerosis].
Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Brain; Combined Modality Therapy; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Administration Schedule; Fingolimod Hydrochloride; Glatiramer Acetate; Glucocorticoids; Humans; Immunosuppressive Agents; Infusions, Intravenous; Interferon-beta; Methylprednisolone; Mitoxantrone; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Peptides; Plasmapheresis; Propylene Glycols; Pulse Therapy, Drug; Sphingosine; Spinal Cord | 2012 |
Oral versus intravenous steroids for treatment of relapses in multiple sclerosis.
Topics: Administration, Oral; Anti-Inflammatory Agents; Glucocorticoids; Humans; Injections, Intravenous; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; Prednisone; Randomized Controlled Trials as Topic; Recurrence | 2012 |
Multiple sclerosis.
Topics: Adrenocorticotropic Hormone; Drug Administration Routes; Humans; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Methylprednisolone; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Randomized Controlled Trials as Topic; Treatment Outcome | 2002 |
[Aggressive multiple sclerosis. Definition and specific therapeutic indication].
Topics: Adjuvants, Immunologic; Adult; Analgesics; Anti-Inflammatory Agents; Clinical Trials as Topic; Diagnosis, Differential; Female; Humans; Immunosuppressive Agents; Interferon-beta; Magnetic Resonance Imaging; Male; Methylprednisolone; Middle Aged; Mitoxantrone; Monitoring, Physiologic; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Neuroprotective Agents; Patient Selection; Placebos; Risk Assessment; Risk Factors; Time Factors | 2004 |
Management of worsening multiple sclerosis with mitoxantrone: a review.
Topics: Anti-Inflammatory Agents; Clinical Trials, Phase II as Topic; Disease Progression; Humans; Immunosuppressive Agents; Methylprednisolone; Mitoxantrone; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Patient Selection; Randomized Controlled Trials as Topic | 2006 |
41 trial(s) available for methylprednisolone and Acute Relapsing Multiple Sclerosis
| Article | Year |
|---|---|
Monthly methylprednisolone in combination with interferon beta or glatiramer acetate for relapsing-remitting multiple sclerosis: A multicentre, single-blind, prospective trial.
Topics: Adult; Drug Therapy, Combination; Female; Glatiramer Acetate; Glucocorticoids; Humans; Immunologic Factors; Interferon-beta; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Outcome Assessment, Health Care; Prospective Studies; Single-Blind Method; Young Adult | 2017 |
Comparison of two high doses of oral methylprednisolone for multiple sclerosis relapses: a pilot, multicentre, randomized, double-blind, non-inferiority trial.
Topics: Adult; Double-Blind Method; Equivalence Trials as Topic; Female; Glucocorticoids; Humans; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Outcome Assessment, Health Care; Pilot Projects; Quality of Life | 2019 |
Efficacy of combination therapy with erythropoietin and methylprednisolone in clinical recovery of severe relapse in multiple sclerosis.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Combined Modality Therapy; Disability Evaluation; Erythropoietin; Female; Follow-Up Studies; Humans; Magnetic Resonance Imaging; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Statistics, Nonparametric; Young Adult | 2014 |
Atorvastatin calcium in combination with methylprednisolone for the treatment of multiple sclerosis relapse.
Topics: Administration, Oral; Adult; Atorvastatin; Brain; Cytokines; Drug Administration Schedule; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Injections, Intravenous; Magnetic Resonance Imaging; Male; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; Pyrroles; Spinal Cord; Treatment Outcome | 2014 |
Oral versus intravenous high-dose methylprednisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomised, controlled, double-blind, non-inferiority trial.
Topics: Administration, Oral; Adolescent; Adult; Double-Blind Method; Female; France; Glucocorticoids; Humans; Infusions, Intravenous; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Treatment Outcome; Young Adult | 2015 |
Effect of treatment with methylprednisolone on the serum levels of IL-12, IL-10 and CCL2 chemokine in patients with multiple sclerosis in relapse.
Topics: Adult; Chemokine CCL2; Enzyme-Linked Immunosorbent Assay; Female; Glucocorticoids; Humans; Interleukin-10; Interleukin-12; Male; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; Time Factors; Treatment Outcome | 2008 |
Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Anti-Inflammatory Agents; Cooperative Behavior; Data Interpretation, Statistical; Disability Evaluation; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Interferon beta-1a; Interferon-beta; Magnetic Resonance Imaging; Male; Methotrexate; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Patient Selection; Treatment Outcome | 2009 |
NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Antibodies; Confidence Intervals; Disability Evaluation; Double-Blind Method; Drug Administration Routes; Drug Therapy, Combination; Europe; Female; Follow-Up Studies; Glucocorticoids; Humans; Interferon beta-1a; Interferon-beta; Kaplan-Meier Estimate; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Psychomotor Performance; Retrospective Studies; Severity of Illness Index; Young Adult | 2009 |
Influence of interferon-beta therapy switching on neutralizing antibody titres: results from the Austrian Switch Study.
Topics: Adult; Antibodies, Neutralizing; Austria; Drug Administration Schedule; Glucocorticoids; Humans; Immunologic Factors; Infusions, Intravenous; Injections, Intramuscular; Injections, Subcutaneous; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Magnetic Resonance Imaging; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Pulse Therapy, Drug; Recurrence; Time Factors; Treatment Outcome | 2009 |
Suppressive effect of glucocorticoids on TNF-alpha production is associated with their clinical effect in multiple sclerosis.
Topics: Adult; Biomarkers; Dexamethasone; Disability Evaluation; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance; Female; Glucocorticoids; Humans; Inflammation Mediators; Leukocytes, Mononuclear; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies; Treatment Outcome; Tumor Necrosis Factor-alpha | 2010 |
Long-term effect of high doses glucocorticosteroids on mRNA expression for IL-6 and IL-8 in relapsed multiple sclerosis patients.
Topics: Adult; Female; Glucocorticoids; Humans; Injections, Intravenous; Interleukin-6; Interleukin-8; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Neuroprotective Agents; Recurrence; RNA, Messenger; Sex Factors | 2010 |
Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
Topics: Adjuvants, Immunologic; Adult; Disability Evaluation; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Interferon beta-1a; Interferon-beta; Kaplan-Meier Estimate; Longitudinal Studies; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Neuroprotective Agents; Severity of Illness Index; Treatment Outcome | 2010 |
Clinical study on CXCL13, CCL17, CCL20 and IL-17 as immune cell migration navigators in relapsing-remitting multiple sclerosis patients.
Topics: Adult; Anti-Inflammatory Agents; Chemokine CCL17; Chemokine CCL20; Chemokine CXCL13; Chemokines; Female; Humans; Interleukin-17; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; ROC Curve; Tension-Type Headache | 2011 |
[Possibilities of treatment of multiple sclerosis exacerbations without corticosteroids: a role of metabolic and antioxidant therapy].
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Antioxidants; Autoantibodies; Cognition; Disease Progression; Drug Combinations; Drug Therapy, Combination; Female; Flavin Mononucleotide; Humans; Inosine Diphosphate; Lipid Peroxidation; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Myelin Sheath; Niacinamide; Pentoxifylline; Succinates; Vitamin B Complex; Young Adult | 2011 |
Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial.
Topics: Adult; Brain; Drug Administration Schedule; Drug Therapy, Combination; Female; Gadolinium; Humans; Immunologic Factors; Immunosuppressive Agents; Interferon beta-1b; Interferon-beta; Magnetic Resonance Imaging; Male; Methylprednisolone; Mitoxantrone; Multiple Sclerosis, Relapsing-Remitting; Neuroimaging; Severity of Illness Index | 2011 |
Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study.
Topics: Adrenal Cortex Hormones; Adult; Antibodies, Monoclonal, Humanized; Female; Glatiramer Acetate; Humans; Immunosuppressive Agents; Inflammation; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Peptides; Prospective Studies; Secondary Prevention; Young Adult | 2011 |
A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Female; Follow-Up Studies; Humans; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Treatment Outcome | 2012 |
Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
Topics: Adult; Antibodies, Monoclonal, Humanized; Brain; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Immunologic Factors; Infusions, Intravenous; Interferon beta-1a; Interferon-beta; Magnetic Resonance Imaging; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; New York; Predictive Value of Tests; Prospective Studies; Pulse Therapy, Drug; Single-Blind Method; Time Factors; Treatment Outcome | 2012 |
Effect of high-dose intravenous methyl-prednisolone treatment on intraocular pressure in multiple sclerosis patients with relapse.
Topics: Adult; Anti-Inflammatory Agents; Female; Humans; Infusions, Intravenous; Intraocular Pressure; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Young Adult | 2012 |
Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNbeta-1b.
Topics: Adjuvants, Immunologic; Adult; Anti-Inflammatory Agents; Atrophy; Brain; Cross-Over Studies; Female; Humans; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Magnetic Resonance Imaging; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting | 2002 |
Interferon gamma and interleukin 4 producing T cells in peripheral blood of multiple sclerosis patients undergoing immunomodulatory treatment.
Topics: Adjuvants, Immunologic; Adult; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Flow Cytometry; Glatiramer Acetate; Glucocorticoids; Humans; Interferon beta-1a; Interferon-beta; Interferon-gamma; Interleukin-4; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Peptides; Reference Values; T-Lymphocyte Subsets; T-Lymphocytes; Th1 Cells; Th2 Cells | 2003 |
Depression-like changes of the sleep-EEG during high dose corticosteroid treatment in patients with multiple sclerosis.
Topics: Adult; Depression; Electroencephalography; Encephalomyelitis; Female; Humans; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Polysomnography; Sleep Wake Disorders; Sleep, REM; Time Factors | 2003 |
Corticosteroids do not prevent optic nerve atrophy following optic neuritis.
Topics: Adult; Evoked Potentials, Visual; Female; Follow-Up Studies; Humans; Image Interpretation, Computer-Assisted; Infusions, Intravenous; Magnetic Resonance Imaging; Male; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; Neuroprotective Agents; Optic Atrophy; Optic Nerve; Optic Neuritis; Retrospective Studies; Treatment Outcome | 2003 |
Serial contrast-enhanced magnetic resonance imaging and spectroscopic imaging of acute multiple sclerosis lesions under high-dose methylprednisolone therapy.
Topics: Acute Disease; Adult; Anti-Inflammatory Agents; Brain Chemistry; Female; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting | 2003 |
A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS.
Topics: Adult; Disability Evaluation; Double-Blind Method; Female; Humans; Immunoglobulins, Intravenous; Injections, Intravenous; Male; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; Neuroprotective Agents; Pilot Projects; Treatment Outcome | 2004 |
The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents; Area Under Curve; Biological Availability; Biotransformation; Female; Humans; Immunosuppressive Agents; Infusions, Intravenous; Liver; Male; Methylprednisolone; Methylprednisolone Hemisuccinate; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Prednisolone; Prednisone | 2004 |
IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Female; Follow-Up Studies; Humans; Immunoglobulins, Intravenous; Life Tables; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Psychomotor Performance; Recurrence; Treatment Failure; Visual Acuity; Walking | 2004 |
Progressive gray matter damage in patients with relapsing-remitting multiple sclerosis: a longitudinal diffusion tensor magnetic resonance imaging study.
Topics: Adult; Axons; Brain; Cohort Studies; Diffusion; Diffusion Magnetic Resonance Imaging; Disease Progression; Female; Follow-Up Studies; Humans; Longitudinal Studies; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Nerve Degeneration; Predictive Value of Tests; Recurrence | 2005 |
Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations.
Topics: Adult; Analysis of Variance; Anti-Inflammatory Agents; Brain; Cross-Over Studies; Dexamethasone; Drug Administration Schedule; Female; Gadolinium; Hormones; Humans; Injections, Intravenous; Magnetic Resonance Imaging; Male; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; Prolactin; Receptors, Cytokine; Time Factors; Treatment Outcome | 2006 |
Short-term effects of methylprednisolone on cerebral volume in multiple sclerosis relapses.
Topics: Adult; Anti-Inflammatory Agents; Cerebral Cortex; Female; Humans; Magnetic Resonance Imaging; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies; Time Factors | 2006 |
Effect of the treatment with methylprednisolone on the cerebrospinal fluid and serum levels of CCL2 and CXCL10 chemokines in patients with active multiple sclerosis.
Topics: Adult; Anti-Inflammatory Agents; Biomarkers; Chemokine CCL2; Chemokine CXCL10; Chemokines, CXC; Chemotaxis, Leukocyte; Controlled Clinical Trials as Topic; Down-Regulation; Female; Humans; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Predictive Value of Tests; Treatment Outcome | 2006 |
CXCL11 (Interferon-inducible T-cell alpha chemoattractant) and interleukin-18 in relapsing-remitting multiple sclerosis patients treated with methylprednisolone.
Topics: Adult; Chemokine CXCL11; Enzyme-Linked Immunosorbent Assay; Female; Humans; Interleukin-18; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Neuroprotective Agents; Statistics, Nonparametric | 2007 |
Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients.
Topics: Adult; Antineoplastic Agents; Antiviral Agents; Azathioprine; Brain; Demography; Disability Evaluation; Drug Therapy, Combination; Female; Follow-Up Studies; Glatiramer Acetate; Humans; Immunosuppressive Agents; Interferon-beta; Magnetic Resonance Imaging; Male; Methotrexate; Methylprednisolone; Mitoxantrone; Multiple Sclerosis, Relapsing-Remitting; Observation; Peptides; Prevalence; Recurrence | 2008 |
Effect of intravenous methylprednisolone on the number, size and confluence of plaques in relapsing-remitting multiple sclerosis.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Central Nervous System; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Magnetic Resonance Imaging; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Nerve Fibers, Myelinated; Recurrence; Severity of Illness Index; Treatment Outcome | 2008 |
Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data.
Topics: Adjuvants, Immunologic; Adolescent; Adult; Anti-Inflammatory Agents; Cooperative Behavior; Data Interpretation, Statistical; Disability Evaluation; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Interferon beta-1a; Interferon-beta; Magnetic Resonance Imaging; Male; Methotrexate; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Patient Selection; Treatment Outcome | 2008 |
Evaluation of response of multiple sclerosis (MS) relapse to oral high-dose methylprednisolone: usefulness of MS functional composite and Expanded Disability Status Scale.
Topics: Administration, Oral; Adult; Disability Evaluation; Dose-Response Relationship, Drug; Evaluation Studies as Topic; Female; Humans; Longitudinal Studies; Male; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; Neuroprotective Agents; Severity of Illness Index | 2008 |
The effect of oral and intravenous methylprednisolone treatment on subsequent relapse rate in multiple sclerosis.
Topics: Administration, Oral; Adult; Female; Humans; Injections, Intravenous; Male; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting | 2000 |
Neurophysiological markers of relapse, remission and long-term recovery processes in MS.
Topics: Anti-Inflammatory Agents; Biomarkers; Cross-Sectional Studies; Evoked Potentials, Visual; Follow-Up Studies; Humans; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; Optic Nerve; Optic Neuritis | 1999 |
Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Atrophy; Brain; Disability Evaluation; Female; Humans; Injections, Intravenous; Magnetic Resonance Imaging; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Pulse Therapy, Drug; Single-Blind Method; Treatment Outcome | 2001 |
Differential treatment effect on measures of neurologic exam, functional impairment and patient self-report in multiple sclerosis.
Topics: Activities of Daily Living; Adult; Aged; Disability Evaluation; Follow-Up Studies; Glucocorticoids; Humans; Injections, Intravenous; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Neurologic Examination; Patient Satisfaction; Treatment Outcome | 2001 |
Clinico-electrophysiological correlates in patients with relapsing-remitting multiple sclerosis.
Topics: Brain; Cyclophosphamide; Disability Evaluation; Drug Combinations; Electric Stimulation; Electrophysiology; Evoked Potentials, Visual; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Magnetics; Male; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting | 2001 |
90 other study(ies) available for methylprednisolone and Acute Relapsing Multiple Sclerosis
| Article | Year |
|---|---|
Methylprednisolone stimulated gene expression (GILZ, MCL-1) and basal cortisol levels in multiple sclerosis patients in relapse are associated with clinical response.
Topics: Administration, Intravenous; Adult; Anti-Inflammatory Agents; Calcitriol; Disability Evaluation; Female; Gene Expression; Humans; Hydrocortisone; Leucine Zippers; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Recurrence | 2021 |
Acute infusion effects in relapsing multiple sclerosis patients receiving alemtuzumab under a modified prophylaxis regimen.
Topics: Alemtuzumab; Canada; Cytokines; Histamine H2 Antagonists; Humans; Methylprednisolone; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Prednisone; Recurrence | 2022 |
Mild COVID-19 symptoms despite treatment with teriflunomide and high-dose methylprednisolone due to multiple sclerosis relapse.
Topics: Adult; Anti-Inflammatory Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Crotonates; Humans; Hydroxybutyrates; Male; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; Nitriles; Pandemics; Pneumonia, Viral; Recurrence; SARS-CoV-2; Toluidines | 2020 |
Prevention of rebound effect after natalizumab withdrawal in multiple sclerosis. Study of two high-dose methylprednisolone schedules.
Topics: Adult; Female; Humans; Magnetic Resonance Imaging; Male; Methylprednisolone; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Retrospective Studies | 2020 |
GABA
Topics: Aged; Alemtuzumab; Autoantibodies; Autoimmune Diseases of the Nervous System; Autoimmunity; B-Lymphocytes; Electroencephalography; Encephalitis; Epilepsia Partialis Continua; Glucocorticoids; Humans; Immunoglobulins, Intravenous; Immunologic Factors; Lymphocyte Activation; Magnetic Resonance Imaging; Male; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; Receptors, GABA-A; Seizures; Status Epilepticus; T-Lymphocytes | 2020 |
Fingolimod-induced immune thrombocytopenic purpura (ITP).
Topics: Adult; Fingolimod Hydrochloride; Glucocorticoids; Humans; Immunoglobulins, Intravenous; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Purpura, Thrombocytopenic, Idiopathic; Sphingosine 1 Phosphate Receptor Modulators; Treatment Outcome | 2020 |
Disease reactivation after switching from natalizumab to daclizumab.
Topics: Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Daclizumab; Drug Substitution; Humans; Immunoglobulin G; Immunologic Factors; Magnetic Resonance Imaging; Male; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; Natalizumab | 2017 |
Management of infusion related reactions associated with alemtuzumab in patients with multiple sclerosis.
Topics: Administration, Intravenous; Administration, Oral; Adult; Alemtuzumab; Anti-Inflammatory Agents; Disability Evaluation; Female; Humans; Immunologic Factors; Male; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; Retrospective Studies; Time Factors; Treatment Outcome | 2017 |
Treatment of multiple sclerosis relapses with high-dose methylprednisolone reduces the evolution of contrast-enhancing lesions into persistent black holes.
Topics: Adolescent; Adult; Aged; Brain; Disease Progression; Female; Follow-Up Studies; Glucocorticoids; Humans; Magnetic Resonance Imaging; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Multivariate Analysis; Neuroprotective Agents; Retrospective Studies; Treatment Outcome; Young Adult | 2018 |
Methylprednisolone-induced acute liver injury in a patient treated for multiple sclerosis relapse.
Topics: Adult; Biopsy; Chemical and Drug Induced Liver Injury; Chronic Disease; Glucocorticoids; Humans; Liver; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting | 2018 |
Cotard syndrome in Tumefactive Multiple Sclerosis- A case report.
Topics: Adult; Affective Disorders, Psychotic; Brain Diseases; Delusions; Depressive Disorder, Major; Female; Glucocorticoids; Humans; Interferon-beta; Magnetic Resonance Imaging; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; Psychotropic Drugs; Syndrome; Treatment Outcome | 2018 |
Serum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: A case report.
Topics: Adult; Alemtuzumab; Female; Glucocorticoids; Humans; Immunologic Factors; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; Serum Sickness | 2018 |
Recurrent atrial fibrillation after pulse corticosteroid treatment for a relapse of multiple sclerosis.
Topics: Adrenal Cortex Hormones; Adult; Atrial Fibrillation; Electrocardiography; Humans; Male; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; Pulse Therapy, Drug; Recurrence; Treatment Outcome | 2019 |
Glucocorticoid Therapy of Multiple Sclerosis Patients Induces Anti-inflammatory Polarization and Increased Chemotaxis of Monocytes.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Chemokine CCL2; Chemotaxis, Leukocyte; Female; Humans; Male; Methylprednisolone; Middle Aged; Monocytes; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Pulse Therapy, Drug; Receptors, CCR2; Receptors, Cell Surface; Receptors, Glucocorticoid; Young Adult | 2019 |
Evaluation of oxidative and nitrosative stress in relapsing remitting multiple sclerosis: effect of corticosteroid therapy.
Topics: Adrenal Cortex Hormones; Adult; Enzyme-Linked Immunosorbent Assay; Female; Humans; Male; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; Nitrosation; Oxidative Stress | 2013 |
Punctate lesion pattern suggestive of perivascular inflammation in acute natalizumab-associated progressive multifocal leukoencephalopathy: productive JC virus infection or preclinical PML-IRIS manifestation?
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Brain; Cerebral Arteries; Combined Modality Therapy; Diagnosis, Differential; Female; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Immune Reconstitution Inflammatory Syndrome; Infusions, Intravenous; Leukoencephalopathy, Progressive Multifocal; Magnetic Resonance Imaging; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Neurologic Examination; Plasma Exchange | 2013 |
Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management?
Topics: Adrenal Cortex Hormones; Female; Humans; Immunity, Cellular; JC Virus; Male; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; T-Lymphocytes | 2013 |
Rebound of disease activity during pregnancy after withdrawal of fingolimod.
Topics: Adult; Anti-Inflammatory Agents; Disability Evaluation; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; Pregnancy; Pregnancy Complications; Propylene Glycols; Sphingosine | 2013 |
First use of alemtuzumab in Balo's concentric sclerosis: a case report.
Topics: Alemtuzumab; Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Brain; Diffuse Cerebral Sclerosis of Schilder; Diffusion Magnetic Resonance Imaging; Disease Progression; Enteral Nutrition; Fatal Outcome; Humans; Magnetic Resonance Imaging; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Muscle Weakness; Neuroprotective Agents; Pneumonia, Aspiration; Treatment Failure | 2013 |
Author Response.
Topics: Adrenal Cortex Hormones; Female; Humans; Immunity, Cellular; JC Virus; Male; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; T-Lymphocytes | 2013 |
Predicting relapsing-remitting dynamics in multiple sclerosis using discrete distribution models: a population approach.
Topics: Anti-Inflammatory Agents; Disease Progression; Humans; Magnetic Resonance Imaging; Methylprednisolone; Models, Biological; Multiple Sclerosis, Relapsing-Remitting; Prednisone; Probability; Software; Statistical Distributions | 2013 |
Relapses in multiple sclerosis: effects of high-dose steroids on cortical excitability.
Topics: Administration, Intravenous; Adult; Aged; Disability Evaluation; Electric Stimulation; Electromyography; Evoked Potentials, Motor; Female; Functional Laterality; Glucocorticoids; Humans; Male; Methylprednisolone; Middle Aged; Motor Cortex; Multiple Sclerosis, Relapsing-Remitting; Neural Inhibition; Pyramidal Tracts; Reaction Time; Young Adult | 2014 |
New regulatory CD19(+)CD25(+) B-cell subset in clinically isolated syndrome and multiple sclerosis relapse. Changes after glucocorticoids.
Topics: Adult; Antigens, CD19; B-Lymphocytes, Regulatory; Cross-Sectional Studies; Demyelinating Diseases; Female; Glucocorticoids; Granzymes; Humans; Interleukin-2 Receptor alpha Subunit; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Perforin; Recurrence; T-Lymphocytes, Regulatory; Young Adult | 2014 |
Drug-induced thrombocytopenia secondary to natalizumab treatment.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Diagnosis, Differential; Female; Humans; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Prednisone; Rituximab; Thrombocytopenia | 2014 |
Incomplete septal cirrhosis after high-dose methylprednisolone therapy and regression of liver injury.
Topics: Administration, Intravenous; Adult; Chemical and Drug Induced Liver Injury; Cholecystectomy; Female; Gallstones; Humans; Liver Cirrhosis; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; Optic Neuritis; Ultrasonography | 2015 |
Glutathione PEGylated liposomal methylprednisolone (2B3-201) attenuates CNS inflammation and degeneration in murine myelin oligodendrocyte glycoprotein induced experimental autoimmune encephalomyelitis.
Topics: Animals; Astrocytes; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Female; Liposomes; Macrophages; Methylprednisolone; Mice; Mice, Inbred C57BL; Multiple Sclerosis, Relapsing-Remitting; Myelin-Oligodendrocyte Glycoprotein; Polyethylene Glycols; Spinal Cord; T-Lymphocytes | 2014 |
Regulation of Treg-associated CD39 in multiple sclerosis and effects of corticotherapy during relapse.
Topics: Administration, Intravenous; Adult; Antigens, CD; Apyrase; Glucocorticoids; Humans; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; T-Lymphocytes, Regulatory; Treatment Outcome | 2015 |
Methylprednisolone-induced Toxic Hepatitis After Intravenous Pulsed Therapy for Multiple Sclerosis Relapses.
Topics: Administration, Intravenous; Adult; Chemical and Drug Induced Liver Injury; Female; Humans; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Pulse Therapy, Drug; Young Adult | 2015 |
A very rare paroxysmal symptom in multiple sclerosis: convergence spasm.
Topics: Adult; Diagnosis, Differential; Diplopia; Female; Glucocorticoids; Humans; Magnetic Resonance Imaging; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; Spasm | 2016 |
Masquerading optic neuritis.
Topics: Female; Glucocorticoids; Hemianopsia; Humans; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Optic Neuritis; Pupil Disorders; Stroke; Visual Acuity; Visual Field Tests; Visual Fields | 2015 |
Oral corticosteroids for multiple sclerosis relapse.
Topics: Female; Glucocorticoids; Humans; Male; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting | 2015 |
Quantitative benefit-risk assessment of methylprednisolone in multiple sclerosis relapses.
Topics: Decision Support Techniques; Glucocorticoids; Humans; Methylprednisolone; Models, Statistical; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Risk Assessment | 2015 |
Changes in Blood B Cell-Activating Factor (BAFF) Levels in Multiple Sclerosis: A Sign of Treatment Outcome.
Topics: Administration, Intravenous; Adult; B-Cell Activating Factor; Biomarkers; Case-Control Studies; Female; Humans; Inflammation Mediators; Male; Methylprednisolone; Models, Biological; Multiple Sclerosis, Relapsing-Remitting; Treatment Outcome | 2015 |
Recovery from an acute relapse is associated with changes in motor resting-state connectivity in multiple sclerosis.
Topics: Adult; Brain Mapping; Disability Evaluation; Female; Humans; Magnetic Resonance Imaging; Male; Methylprednisolone; Motor Cortex; Multiple Sclerosis, Relapsing-Remitting; Neural Pathways | 2016 |
[Corticotherapy and suicidal behavior: A case report].
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Depressive Disorder, Major; Female; Humans; Injections, Intravenous; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Suicidal Ideation; Suicide, Attempted | 2016 |
The impact of multiple sclerosis relapse treatment on migration of effector T cells--Preliminary study.
Topics: CD4-Positive T-Lymphocytes; Cell Movement; Chemokines; Chemotaxis, Leukocyte; Dose-Response Relationship, Drug; Glucocorticoids; Humans; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; Receptors, Chemokine; T-Lymphocyte Subsets | 2016 |
Patient-reported adverse effects of high-dose intravenous methylprednisolone treatment: a prospective web-based multi-center study in multiple sclerosis patients with a relapse.
Topics: Activities of Daily Living; Administration, Intravenous; Adult; Aged; Anti-Inflammatory Agents; Disabled Persons; Dose-Response Relationship, Drug; Female; Humans; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Online Systems; Prospective Studies; Self Report; Surveys and Questionnaires | 2016 |
The effects of thrombomodulin and activated protein C on the pathogenesis of multiple sclerosis.
Topics: Adult; Anti-Inflammatory Agents; Disability Evaluation; Female; Humans; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Protein C; Thrombomodulin | 2016 |
Intravenous Methylprednisolone-Induced Nocturnal Sinus Bradycardia in a Multiple Sclerosis Patient.
Topics: Administration, Intravenous; Anti-Inflammatory Agents; Bradycardia; Female; Humans; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting | 2016 |
Regulatory Cell Populations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients: Effect of Disease Activity and Treatment Regimens.
Topics: Adult; Autoantigens; CD4-Positive T-Lymphocytes; Female; Flow Cytometry; Forkhead Transcription Factors; Humans; Interleukin-2 Receptor alpha Subunit; Leukocytes, Mononuclear; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Myelin Basic Protein; Myelin-Oligodendrocyte Glycoprotein; Natalizumab; T-Lymphocytes, Regulatory | 2016 |
Toll-like receptor (TLR)7 and TLR9 agonists enhance interferon (IFN) beta-1a's immunoregulatory effects on B cells in patients with relapsing-remitting multiple sclerosis (RRMS).
Topics: B-Lymphocytes; Case-Control Studies; CD4 Antigens; Cytokines; Drug Synergism; Female; Glatiramer Acetate; Guanosine; Humans; Immunologic Factors; Interferon Regulatory Factor-7; Interferon-beta; Male; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; Myeloid Differentiation Factor 88; STAT1 Transcription Factor; Tetraspanin 29; Toll-Like Receptor 7; Toll-Like Receptor 9 | 2016 |
Interleukins 17 and 10 in a sample of Egyptian relapsing remitting multiple sclerosis patients.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Case-Control Studies; Disability Evaluation; Egypt; Enzyme-Linked Immunosorbent Assay; Female; Humans; Interleukin-10; Interleukin-17; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Statistics, Nonparametric; Young Adult | 2016 |
Genes differentially expressed by methylprednisolone in vivo in CD4 T lymphocytes from multiple sclerosis patients: potential biomarkers.
Topics: Administration, Intravenous; Adult; Biomarkers; CD4-Positive T-Lymphocytes; Down-Regulation; Female; Gene Expression; Humans; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Signal Transduction; Transcription, Genetic; Up-Regulation | 2018 |
Peripheral blood cell immunomarkers in the course of methylprednisolone treatment of multiple sclerosis relapses.
Topics: Adult; Anti-Inflammatory Agents; Antigens, CD; Biomarkers; Female; Humans; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; T-Lymphocytes | 2008 |
Clinical-radiologic heterogeneity of occipital neuralgiform pain as multiple sclerosis relapse.
Topics: Adult; Aged; Cervical Vertebrae; Female; Humans; Magnetic Resonance Imaging; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Neuralgia; Neuroprotective Agents; Occipital Bone; Spinal Cord | 2009 |
Changes in circulating dendritic cells and B-cells in patients with multiple sclerosis relapse during corticosteroid therapy.
Topics: Adrenal Cortex Hormones; Adult; Antigens, CD1; Antigens, CD19; Antigens, Surface; B-Lymphocytes; Dendritic Cells; Female; Flow Cytometry; Glycoproteins; Humans; Immunophenotyping; Injections, Intravenous; Lectins, C-Type; Male; Membrane Glycoproteins; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Receptors, Immunologic; Statistics, Nonparametric; Young Adult | 2009 |
Home administration of intravenous methylprednisolone for multiple sclerosis relapses: the experience of French multiple sclerosis networks.
Topics: Adult; Cost Savings; Databases, Factual; Female; France; Geographic Information Systems; Glucocorticoids; Health Expenditures; Home Care Services; Humans; Injections, Intravenous; Male; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; National Health Programs; Outcome and Process Assessment, Health Care; Patient Satisfaction; Secondary Prevention; Surveys and Questionnaires | 2009 |
Glucocorticoid treatment restores the impaired suppressive function of regulatory T cells in patients with relapsing-remitting multiple sclerosis.
Topics: Acute Disease; Autoimmunity; Case-Control Studies; Flow Cytometry; Forkhead Transcription Factors; Glucocorticoids; Humans; Immunization; Immunophenotyping; Interleukin-10; Interleukin-2 Receptor alpha Subunit; Lymphocyte Count; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; Regression Analysis; T-Lymphocytes, Regulatory | 2009 |
Effect of high-dose methylprednisolone treatment on Th17 cells in patients with multiple sclerosis in relapse.
Topics: Adult; Anti-Inflammatory Agents; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Humans; Interleukin-7; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Nuclear Receptor Subfamily 1, Group F, Member 3; Receptors, Interleukin; T-Lymphocytes, Helper-Inducer | 2009 |
Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Antineoplastic Agents; Child; Cohort Studies; Female; Humans; Interferon Type I; Leukemia, Myeloid, Acute; Male; Mediterranean Region; Methylprednisolone; Middle Aged; Mitoxantrone; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies; Recombinant Proteins; Risk Assessment; Young Adult | 2009 |
Symptomatic, steroid-induced, multifocal diaphyseal osteonecrosis in a patient with multiple sclerosis.
Topics: Adrenal Cortex Hormones; Adult; Diaphyses; Female; Femur; Humans; Magnetic Resonance Imaging; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; Orthopedic Procedures; Osteonecrosis; Pain; Pain Measurement; Pulse Therapy, Drug; Talus; Tibia; Treatment Outcome | 2010 |
Treatment of steroid unresponsive relapse with plasma exchange in aggressive multiple sclerosis.
Topics: Adult; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Glucocorticoids; Humans; Male; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; Plasma Exchange; Recurrence; Time Factors; Young Adult | 2010 |
CCL5, CXCL10 and CXCL11 chemokines in patients with active and stable relapsing-remitting multiple sclerosis.
Topics: Acute Disease; Adult; Anti-Inflammatory Agents; Chemokine CCL5; Chemokine CXCL10; Chemokine CXCL11; Chemokines; Female; Humans; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Up-Regulation; Young Adult | 2011 |
Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis.
Topics: Antibodies, Neutralizing; Azathioprine; Humans; Immunosuppressive Agents; Interferon-beta; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting | 2010 |
Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis.
Topics: Adult; Cross-Sectional Studies; Demyelinating Diseases; Diffusion Magnetic Resonance Imaging; Disability Evaluation; Enzyme-Linked Immunosorbent Assay; Female; Glucocorticoids; Humans; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Osteopontin; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Up-Regulation | 2011 |
The balance of pro-inflammatory and trophic factors in multiple sclerosis patients: effects of acute relapse and immunomodulatory treatment.
Topics: Adult; Brain-Derived Neurotrophic Factor; Case-Control Studies; Cell Separation; Cells, Cultured; Ciliary Neurotrophic Factor; Drug Therapy, Combination; Female; Flow Cytometry; Glucocorticoids; Humans; Immunologic Factors; Inflammation Mediators; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Leukocytes, Mononuclear; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Nerve Growth Factors; Nitric Oxide Synthase Type II; Treatment Outcome; Tumor Necrosis Factor-alpha; Young Adult | 2011 |
Dramatic worsening following plasma exchange in severe post-natalizumab withdrawal multiple sclerosis relapse.
Topics: Adult; Antibodies, Monoclonal, Humanized; Combined Modality Therapy; Female; Humans; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Plasma Exchange; Pregnancy; Recurrence | 2011 |
Psychotic reaction as a manifestation of multiple sclerosis relapse treated with plasma exchange.
Topics: Adult; Brain; Humans; Magnetic Resonance Imaging; Male; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; Neuroprotective Agents; Plasma Exchange; Psychotic Disorders; Spinal Cord | 2012 |
Natalizumab-associated PML identified in the presymptomatic phase using MRI surveillance.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Humanized; Electroencephalography; Female; Humans; Immune Reconstitution Inflammatory Syndrome; Interferon-beta; JC Virus; Magnetic Resonance Imaging; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Natalizumab; Posterior Leukoencephalopathy Syndrome | 2012 |
A review of interferon use in patients with relapsing remitting multiple sclerosis in the Canterbury region, New Zealand: 2000-2006.
Topics: Adult; Disability Evaluation; Eligibility Determination; Female; Humans; Immunologic Factors; Interferon-beta; Male; Medical Audit; Medication Adherence; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; National Health Programs; Neuroprotective Agents; New Zealand; Recurrence; Retrospective Studies; Treatment Outcome | 2012 |
It is better to be in a clinical trial than not: lessons learnt from clinical neurology--the management of acute multiple sclerosis relapses.
Topics: Adult; Ambulatory Care; Cohort Studies; Female; Home Care Services; Humans; Infusions, Intravenous; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Neuroprotective Agents; Patient Satisfaction; Quality of Health Care; Randomized Controlled Trials as Topic; Recurrence | 2012 |
Asymptomatic supratentorial arachnoid cyst and symptomatic demyelination plaques: which one needs treatment?
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents; Arachnoid Cysts; Asymptomatic Diseases; Cerebral Ventricles; Comorbidity; Cooperative Behavior; Female; Frontal Lobe; Humans; Image Interpretation, Computer-Assisted; Incidental Findings; Infusions, Intravenous; Interdisciplinary Communication; Magnetic Resonance Imaging; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; Prednisolone; Radiographic Image Enhancement | 2010 |
Central nervous system B-cell lymphoma in multiple sclerosis.
Topics: Anti-Inflammatory Agents; Central Nervous System Neoplasms; Glatiramer Acetate; Humans; Interferon-beta; Lymphoma, B-Cell; Magnetic Resonance Imaging; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Neurologic Examination; Peptides | 2012 |
Impairment of JCV-specific T-cell response by corticotherapy: effect on PML-IRIS management?
Topics: Adrenal Cortex Hormones; Adult; Female; Humans; Immunity, Cellular; JC Virus; Lymphocyte Activation; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; T-Lymphocytes | 2012 |
Comment: avoiding detrimental effects of corticosteroids on JC virus T-cell responses--primum non nocere.
Topics: Adrenal Cortex Hormones; Female; Humans; Immunity, Cellular; JC Virus; Male; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; T-Lymphocytes | 2012 |
Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone.
Topics: Adult; Brain; Cerebral Ventricles; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Injections, Intravenous; Magnetic Resonance Imaging; Male; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; Neuroprotective Agents; Retrospective Studies | 2002 |
[Effect of methylprednisolone on emotional functioning of patients with multiple sclerosis].
Topics: Adult; Anxiety; Case-Control Studies; Cognition Disorders; Depression; Emotions; Female; Glucocorticoids; Humans; Infusions, Intravenous; Male; Mental Disorders; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Neuroprotective Agents; Neuropsychological Tests; Sciatica; Time Factors | 2002 |
Parkinsonism as a manifestation of multiple sclerosis.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Neurologic Examination; Parkinsonian Disorders | 2003 |
Serial gadolinium-enhanced MRI in acute attack of multiple sclerosis treated with plasma exchange.
Topics: Acute Disease; Adult; Anti-Inflammatory Agents; Antineoplastic Agents; Gadolinium; Humans; Magnetic Resonance Imaging; Male; Methylprednisolone; Mitoxantrone; Multiple Sclerosis, Relapsing-Remitting; Plasma Exchange | 2003 |
Longitudinal study of chemokine receptor expression on peripheral lymphocytes in multiple sclerosis: CXCR3 upregulation is associated with relapse.
Topics: Adult; Aged; Anti-Inflammatory Agents; Biomarkers; Female; Flow Cytometry; Humans; Interferon-gamma; Interleukin-4; Longitudinal Studies; Lymphocytes; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Receptors, CCR2; Receptors, CCR5; Receptors, Chemokine; Receptors, CXCR3; Recurrence; Up-Regulation | 2003 |
Cost of managing an episode of relapse in multiple sclerosis in the United States.
Topics: Adult; Aftercare; Ambulatory Care; Cost of Illness; Direct Service Costs; Drug Costs; Episode of Care; Female; Hospital Costs; Hospitalization; Humans; Insurance, Health; Male; Managed Care Programs; Medicaid; Medicare; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Recurrence; United States | 2003 |
Hypersexual sensations and behavior in a multiple sclerosis exacerbation: a case report.
Topics: Anti-Inflammatory Agents; Brain; Female; Hormones; Humans; Libido; Magnetic Resonance Imaging; Masturbation; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Neurologic Examination; Prednisone; Sexual Behavior; Sexual Dysfunction, Physiological; Vagina | 2004 |
Acute aphasia in multiple sclerosis: A multicenter study of 22 patients.
Topics: Acute Disease; Adult; Anti-Inflammatory Agents; Aphasia; Azathioprine; Brain; Cohort Studies; Comorbidity; Disease Progression; Female; France; Humans; Immunologic Factors; Immunosuppressive Agents; Interferon-beta; Magnetic Resonance Imaging; Male; Methylprednisolone; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Prevalence; Recovery of Function | 2004 |
Clinical impact of intravenous methylprednisolone in attacks of multiple sclerosis.
Topics: Adult; Disability Evaluation; Female; Humans; Injections, Intravenous; Male; Methylprednisolone; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Neuroprotective Agents; Predictive Value of Tests; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2004 |
[Relapsing remitting multiple sclerosis or multiphasic disseminated encephalomyelitis?].
Topics: Adolescent; Anti-Inflammatory Agents; Brain; Diagnosis, Differential; Encephalomyelitis, Acute Disseminated; Humans; Magnetic Resonance Imaging; Male; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting | 2005 |
[Bilateral third cranial nerve palsy triggered by an acute relapse of multiple sclerosis].
Topics: Anti-Inflammatory Agents; Blepharoptosis; Humans; Magnetic Resonance Imaging; Male; Mesencephalon; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Oculomotor Nerve Diseases | 2005 |
Quantification of central motor conduction deficits in multiple sclerosis patients before and after treatment of acute exacerbation by methylprednisolone.
Topics: Adult; Dose-Response Relationship, Drug; Evoked Potentials, Motor; Female; Humans; Infusions, Intravenous; Isometric Contraction; Male; Methylprednisolone; Middle Aged; Motor Neuron Disease; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Neural Conduction; Optic Neuritis; Pyramidal Tracts; Treatment Outcome | 2006 |
IL-6 and CCL2 levels in CSF are associated with the clinical course of MS: implications for their possible immunopathogenic roles.
Topics: Adolescent; Adult; Biomarkers; Chemokine CCL2; Female; Humans; Interferon-beta; Interleukin-6; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Neurofilament Proteins; Prospective Studies | 2006 |
Changes in LORETA and conventional patterns of P600 after steroid treatment in multiple sclerosis patients.
Topics: Acoustic Stimulation; Adult; Anti-Inflammatory Agents; Electroencephalography; Evoked Potentials; Female; Humans; Magnetic Resonance Imaging; Male; Memory, Short-Term; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; Neuropsychological Tests; Psychomotor Performance; Steroids | 2007 |
Steroid-responsive neurologic relapses in a child with a proteolipid protein-1 mutation.
Topics: Amino Acid Substitution; Central Nervous System; Cerebellar Diseases; Child; Disease Progression; DNA Mutational Analysis; Exons; Genetic Predisposition to Disease; Humans; Inflammation; Interferon beta-1a; Interferon-beta; Magnetic Resonance Imaging; Male; Membrane Proteins; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; Mutation; Myelin Proteolipid Protein; Neuroprotective Agents; Oligoclonal Bands; Remission Induction; Steroids; Treatment Outcome | 2007 |
Glucocorticoid treatment reduces T-bet and pSTAT1 expression in mononuclear cells from relapsing remitting multiple sclerosis patients.
Topics: Adult; Annexin A5; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cells, Cultured; Cytokines; Down-Regulation; Female; Glucocorticoids; Humans; Leukocytes, Mononuclear; Male; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; Phosphorylation; Signal Transduction; STAT1 Transcription Factor; STAT3 Transcription Factor; T-Box Domain Proteins | 2007 |
Short-term combination of glatiramer acetate with i.v. steroid treatment preceding treatment with GA alone assessed by MRI-disease activity in patients with relapsing-remitting multiple sclerosis.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Drug Therapy, Combination; Female; Glatiramer Acetate; Humans; Injections, Intravenous; Magnetic Resonance Imaging; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Peptides; Treatment Outcome | 2008 |
Oral prednisone taper following intravenous steroids fails to improve disability or recovery from relapses in multiple sclerosis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents; Drug Therapy, Combination; Female; Humans; Injections, Intravenous; Male; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; Prednisone; Recovery of Function; Retrospective Studies | 2008 |
CD80 (B7-1) and CD86 (B7-2) expression in multiple sclerosis patients: clinical subtype specific variation in peripheral monocytes and B cells and lack of modulation by high dose methylprednisolone.
Topics: Antigens, CD; B-Lymphocytes; B7-1 Antigen; B7-2 Antigen; Case-Control Studies; Female; Humans; Interferon-gamma; Male; Membrane Glycoproteins; Methylprednisolone; Monocytes; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting | 1999 |
Soluble and cell surface ICAM-3 in blood and cerebrospinal fluid of patients with multiple sclerosis: influence of methylprednisolone treatment and relevance as markers for disease activity.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antigens, CD; Antigens, Differentiation; Biomarkers; CD3 Complex; Cell Adhesion Molecules; Disease Progression; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Humans; Lipopolysaccharide Receptors; Lymphocytes; Methylprednisolone; Middle Aged; Monocytes; Multiple Sclerosis, Relapsing-Remitting | 2000 |
Reversibility of acute demyelinating lesions in relapsing-remitting multiple sclerosis.
Topics: Adult; Brain; Demyelinating Diseases; Female; Follow-Up Studies; Glucocorticoids; Humans; Injections, Intravenous; Magnetic Resonance Imaging; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; Recurrence; Remission Induction; Severity of Illness Index | 2000 |
Recovery following acute exacerbations of multiple sclerosis: from impairment to quality of life.
Topics: Adult; Female; Glucocorticoids; Humans; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Neuroprotective Agents; Pilot Projects; Quality of Life; Severity of Illness Index | 2001 |
Interferon-beta treatment of experimental autoimmune encephalomyelitis leads to rapid nonapoptotic termination of T cell infiltration.
Topics: Animals; Apoptosis; Blood-Brain Barrier; Cells, Cultured; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Female; Immunohistochemistry; Immunologic Factors; Interferon-beta; Macrophages; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; Neuroprotective Agents; Rats; Rats, Inbred Lew; T-Lymphocytes; Tumor Necrosis Factor-alpha | 2001 |
Rapid weaning from mechanical ventilator in acute cervical cord multiple sclerosis lesion after steroids.
Topics: Acute Disease; Glucocorticoids; Humans; Infusions, Intravenous; Male; Methylprednisolone; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Respiration, Artificial; Respiratory Insufficiency; Spinal Cord; Ventilator Weaning | 2001 |
A case of multiple sclerosis with cerebral venous thrombosis: the role of lumbar puncture and high-dose steroids.
Topics: Adult; Cerebral Veins; Disability Evaluation; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Methylprednisolone; Multiple Sclerosis, Relapsing-Remitting; Neuroprotective Agents; Prednisolone; Spinal Puncture; Venous Thrombosis | 2002 |